{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:27:01Z","timestamp":1790000821170,"version":"4.0.1"},"reference-count":114,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T00:00:00Z","timestamp":1656288000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["CPT Pharmacom &amp; Syst Pharma"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Physiologically\u2010based pharmacokinetic models combine knowledge about physiology, drug product properties, such as physicochemical parameters, absorption, distribution, metabolism, excretion characteristics, formulation attributes, and trial design or dosing regimen to mechanistically simulate drug pharmacokinetics (PK). The current work describes the development of a multiphase, multilayer mechanistic dermal absorption (MPML MechDermA) model within the Simcyp Simulator capable of simulating uptake and permeation of drugs through human skin following application of drug products to the skin. The model was designed to account for formulation characteristics as well as body site\u2010 and sex\u2010 population variability to predict local and systemic bioavailability. The present report outlines the structure and assumptions of the MPML MechDermA model and includes results from simulations comparing absorption at multiple body sites for two compounds, caffeine and benzoic acid, formulated as solutions. Finally, a model of the Feldene (piroxicam) topical gel, 0.5% was developed and assessed for its ability to predict both plasma and local skin concentrations when compared to in vivo PK data.<\/jats:p>","DOI":"10.1002\/psp4.12814","type":"journal-article","created":{"date-parts":[[2022,6,7]],"date-time":"2022-06-07T09:15:35Z","timestamp":1654593335000},"page":"1060-1084","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Multi\u2010phase multi\u2010layer mechanistic dermal absorption (MPML MechDermA) model to predict local and systemic exposure of drug products applied on skin"],"prefix":"10.1002","volume":"11","author":[{"given":"Nikunjkumar","family":"Patel","sequence":"first","affiliation":[{"name":"Simcyp Division Certara UK  Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James F.","family":"Clarke","sequence":"additional","affiliation":[{"name":"Simcyp Division Certara UK  Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzaneh","family":"Salem","sequence":"additional","affiliation":[{"name":"Simcyp Division Certara UK  Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tariq","family":"Abdulla","sequence":"additional","affiliation":[{"name":"Simcyp Division Certara UK  Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5555-8771","authenticated-orcid":false,"given":"Frederico","family":"Martins","sequence":"additional","affiliation":[{"name":"Simcyp Division Certara UK  Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Arora","sequence":"additional","affiliation":[{"name":"Simcyp Division Certara UK  Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleftheria","family":"Tsakalozou","sequence":"additional","affiliation":[{"name":"Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research U.S. Food and Drug Administration (FDA)  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arran","family":"Hodgkinson","sequence":"additional","affiliation":[{"name":"Simcyp Division Certara UK  Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Arjmandi\u2010Tash","sequence":"additional","affiliation":[{"name":"Simcyp Division Certara UK  Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinziana","family":"Cristea","sequence":"additional","affiliation":[{"name":"Simcyp Division Certara UK  Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Ghosh","sequence":"additional","affiliation":[{"name":"Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research U.S. Food and Drug Administration (FDA)  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khondoker","family":"Alam","sequence":"additional","affiliation":[{"name":"Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research U.S. Food and Drug Administration (FDA)  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3562-8175","authenticated-orcid":false,"given":"Sam G.","family":"Raney","sequence":"additional","affiliation":[{"name":"Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research U.S. Food and Drug Administration (FDA)  Silver Spring Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3443-0194","authenticated-orcid":false,"given":"Masoud","family":"Jamei","sequence":"additional","affiliation":[{"name":"Simcyp Division Certara UK  Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Polak","sequence":"additional","affiliation":[{"name":"Simcyp Division Certara UK  Sheffield UK"},{"name":"Faculty of Pharmacy Jagiellonian University Medical College  Krakow Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,6,27]]},"reference":[{"key":"e_1_2_12_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/psp.2013.41"},{"key":"e_1_2_12_3_1","doi-asserted-by":"publisher","DOI":"10.2133\/dmpk.24.53"},{"key":"e_1_2_12_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2019.105170"},{"key":"e_1_2_12_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2018.06.013"},{"key":"e_1_2_12_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12600"},{"key":"e_1_2_12_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2017.07.035"},{"key":"e_1_2_12_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1013"},{"key":"e_1_2_12_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2018.10.033"},{"key":"e_1_2_12_10_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-019-0298-x"},{"key":"e_1_2_12_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40495-016-0059-9"},{"key":"e_1_2_12_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.2010.298"},{"key":"e_1_2_12_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23570"},{"key":"e_1_2_12_14_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.115.065920"},{"key":"e_1_2_12_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12204"},{"key":"e_1_2_12_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12010019"},{"key":"e_1_2_12_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/jat.3004"},{"key":"e_1_2_12_18_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015810312465"},{"key":"e_1_2_12_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20509"},{"key":"e_1_2_12_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20883"},{"key":"e_1_2_12_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11095-014-1575-0"},{"key":"e_1_2_12_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2018.07.015"},{"key":"e_1_2_12_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2012.04.009"},{"key":"e_1_2_12_24_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018981515480"},{"key":"e_1_2_12_25_1","volume-title":"Draft Guidance on Acyclovir Topical Cream, 5%, Recommended Dec 2014","author":"FDA","year":"2016"},{"key":"e_1_2_12_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-015-0292-0"},{"key":"e_1_2_12_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2020.01.062"},{"key":"e_1_2_12_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1364"},{"key":"e_1_2_12_29_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-008-9010-2"},{"key":"e_1_2_12_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1282"},{"key":"e_1_2_12_31_1","volume-title":"Locally Acting Physiologically\u2010Based Pharmacokinetic Modeling: Summary of FY2019 Activities","author":"GDUFA","year":"2019"},{"key":"e_1_2_12_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23155"},{"key":"e_1_2_12_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12100942"},{"key":"e_1_2_12_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2021.02.016"},{"key":"e_1_2_12_35_1","unstructured":"SalemF PatelN PolakS.Development of a PBPK model for topical lidocaine in order to predict systemic absorption in healthy volunteers geriatrics and paediatrics. ASCPT; 2019 March 13\u201316; Washington DC;2019."},{"key":"e_1_2_12_36_1","unstructured":"PolakS PatelN.Development of the dermal absorption model for the ketoprofen local and systemic exposure prediction. Skin Forum Annual Meeting; 2018 June 20\u201321; Tallin Estonia;2018."},{"key":"e_1_2_12_37_1","unstructured":"PolakS PatelN Rowland YeoK JameiM.Assessing formulation attributes' impact on local and systemic exposure of clindamycin after topical application of pro\u2010drug clindamycin phosphate using PBPK modelling. Controlled Release Society Annual Meeting and Exposition; 2018 July 22\u201324; New York NY;2018."},{"key":"e_1_2_12_38_1","unstructured":"PatelN S.Cristea R.Rose et al.Mechanistic modelling of dermal drug absorption using the Simcyp Multi\u2010phase Multi\u2010layer MechDermA model: Case study of a transdermal patch formulation of weak base drug timolol. Gordon Research Conference;2015."},{"key":"e_1_2_12_39_1","article-title":"Multi\u2010phase multi\u2010layer mechanistic physiologically based pharmacokinetic dermal absorption model verification including inter and intra individual variability assessment using nicotine as a model drug","volume":"360","author":"Martins F","year":"2018","journal-title":"AAPS PharmSci"},{"key":"e_1_2_12_40_1","unstructured":"AroraS PatelN PolakS.Performance verification of mechanistic dermal physiological based pharmacokinetic (PBPK) model for enhanced understanding of dermal absorption: prediction of local tissue exposure after topical application of acitretin. Ninth American Conference on Pharmacometrics (ACoP9); 2018 October 6\u201011; San Diego;2018."},{"key":"e_1_2_12_41_1","unstructured":"MartinsF PatelN JameiM PolakS.Development and validation of a dermal PBPK model for prediction of the hair follicular absorption of caffeine: application of the Simcyp MPML MechDermA model. 14th ISSX; 2017 June 26\u201029; Cologne Germany;2017."},{"key":"e_1_2_12_42_1","unstructured":"MartinsF PatelN SalemF JameiM PolakS.Multi\u2010phase multi\u2010layer MechDermA model: development verification and application of a PBPK\u2010PD model of dermal absorption for transdermal product assessment. Perspective in Percutaneous Penetration; 2018 April 4; La Grande Motte France;2018."},{"key":"e_1_2_12_43_1","unstructured":"PatelN BenkaliK Osman\u2010PonchetH NeuhoffS PolakS WagnerN.Development and verification of PBPK model for a topical ceram formulation of trifarotene to simulate local and systemic exposure and model application to simulate potential CYP\u2010mediated drug\u2013drug interactions. AAPS Annual Meeting and Exposition; 2018 April 4; La Grande Motte France;2017."},{"key":"e_1_2_12_44_1","unstructured":"MartinsF PatelN SalemF JameiM PolakS.Multi\u2010phase Multi\u2010layer MechDermA model: development verification and application of pbpk\u2010pd model of dermal absorption for topical product assessment. Gordon Research Conference; Paris;2016."},{"key":"e_1_2_12_45_1","unstructured":"MartinsF PatelN CristeaS PolakS.Development and validation of dermal PBPK model towards virtual bioequivalence assessment: prediction of dermal drug absorption of various ibuprofen formulations using Simcyp MechDermA model. DMDG; 2016 October 19\u201321;2016."},{"key":"e_1_2_12_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20502"},{"key":"e_1_2_12_47_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20322"},{"key":"e_1_2_12_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12102"},{"key":"e_1_2_12_49_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejps.2009.12.002"},{"key":"e_1_2_12_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcm.2011.02.003"},{"key":"e_1_2_12_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0013-9351(05)80112-4"},{"key":"e_1_2_12_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600590514"},{"key":"e_1_2_12_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600620106"},{"key":"e_1_2_12_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.430130203"},{"key":"e_1_2_12_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-68682-5"},{"key":"e_1_2_12_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08311.x"},{"key":"e_1_2_12_57_1","doi-asserted-by":"publisher","DOI":"10.1159\/000211296"},{"key":"e_1_2_12_58_1","doi-asserted-by":"publisher","DOI":"10.1208\/ps030213"},{"key":"e_1_2_12_59_1","doi-asserted-by":"publisher","DOI":"10.1021\/js960198e"},{"key":"e_1_2_12_60_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018917729477"},{"key":"e_1_2_12_61_1","doi-asserted-by":"publisher","DOI":"10.1021\/js980236p"},{"key":"e_1_2_12_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/0378-5173(89)90069-0"},{"key":"e_1_2_12_63_1","unstructured":"GajjarRM.Absorption and Evaporation of Volatile Organic Solvents from Human Skin In Vitro. PhD thesis University of Cincinnati;2010."},{"key":"e_1_2_12_64_1","volume-title":"Technical Guidance for Hazards Analysis","author":"US EPA","year":"1987"},{"key":"e_1_2_12_65_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.7b00406"},{"key":"e_1_2_12_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xphs.2018.11.034"},{"key":"e_1_2_12_67_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.0c00043"},{"key":"e_1_2_12_68_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23106"},{"key":"e_1_2_12_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2007.06.020"},{"key":"e_1_2_12_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2011.04128.x"},{"key":"e_1_2_12_71_1","article-title":"Predicting depth resolved concentrations in the dermis using PBPK modelling: design, development and verification of the model with five drugs","volume":"360","author":"Clarke JF","year":"2018","journal-title":"AAPS PharmSci"},{"key":"e_1_2_12_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03188792"},{"key":"e_1_2_12_73_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1983.tb02191.x"},{"key":"e_1_2_12_74_1","first-page":"303","article-title":"Comparative steady state pharmacokinetic study of piroxicam and flurbiprofen in normal subjects","volume":"4","author":"Rogers HJ","year":"1981","journal-title":"Eur J Rheumatol Inflamm"},{"key":"e_1_2_12_75_1","first-page":"309","article-title":"The steady\u2010state pharmacokinetics of piroxicam: effect of food and iron","volume":"4","author":"Tilstone WJ","year":"1981","journal-title":"Eur J Rheumatol Inflamm"},{"key":"e_1_2_12_76_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01062535"},{"key":"e_1_2_12_77_1","unstructured":"Pfizer.Safety Data Sheet\u2013Feldene Gel.2014Accessed March 30 2021 Available from:https:\/\/safetydatasheets.pfizer.com\/MyDocuments\/DownloadSingleFile?content=2EC721FD\u20104352\u2010403D\u2010B2E3\u2010EB415AD6BFDC_PDF"},{"key":"e_1_2_12_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9063(199901)55:1<78::AID-PS853>3.0.CO;2-7"},{"key":"e_1_2_12_79_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13065-015-0085-4"},{"key":"e_1_2_12_80_1","volume-title":"UFZ\u2010LSER database v 3.2.1","author":"Ulrich N","year":"2017"},{"key":"e_1_2_12_81_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.114.058099"},{"key":"e_1_2_12_82_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.904"},{"key":"e_1_2_12_83_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.2600760608"},{"key":"e_1_2_12_84_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00226333"},{"key":"e_1_2_12_85_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF03258422"},{"key":"e_1_2_12_86_1","doi-asserted-by":"publisher","DOI":"10.1159\/000211316"},{"key":"e_1_2_12_87_1","first-page":"117","article-title":"The pharmacokinetics of 0.5% piroxicam gel in humans","volume":"8","author":"Kanazawa M","year":"1987","journal-title":"Eur J Rheumatol Inflamm"},{"key":"e_1_2_12_88_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1240"},{"key":"e_1_2_12_89_1","unstructured":"AbdullaT PatelN PolakS MartinsF Rostami\u2010HodjeganA JameiM.Quantitative prediction of dermal drug absorption using MPML MechDermA model: relative effects of applications site on rivastigmine pharmacokinetics from a transdermal delivery system. AAPS Annual Meeting & Exposition; 2017 November 12\u201315; San Diego USA;2017."},{"key":"e_1_2_12_90_1","doi-asserted-by":"publisher","DOI":"10.1159\/000489513"},{"key":"e_1_2_12_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.toxlet.2014.06.008"},{"key":"e_1_2_12_92_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00420-010-0546-y"},{"key":"e_1_2_12_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0536.2008.01348.x"},{"key":"e_1_2_12_94_1","article-title":"Evaluation of methamphetamine and amphetamine disposition discrepancy upon selegiline transdermal patch administration in healthy volunteers versus special populations using PBPK modelling","volume":"360","author":"Puttrevu SK","year":"2019","journal-title":"AAPS PharmSci"},{"key":"e_1_2_12_95_1","unstructured":"PolakS.PBPK model development and evaluation for the topically applied nimesulide gel\u2013assessment of the local tissue penetration and systemic absorption. Controlled Release Society Annual Meeting; Valencia Spain;2019."},{"key":"e_1_2_12_96_1","unstructured":"MartinsF PatelN SalemF JameiM PolakS.Multi\u2010phase multi\u2010layer MechDermA model: development verification and application of a PBPK\u2010PD model of dermal absorption for transdermal product assessment. Gordon Research Seminar on Barrier Function of Mammalian Skin; Waterville Valley NH USA;2017."},{"key":"e_1_2_12_97_1","unstructured":"PolakS PatelN Rowland YeoK JameiM.Towards virtual exposure assesment of dermally applied drugs\u2013PBPK model of buprenorphine transdermal patches. American Conference on Pharmacometrics; Fort Lauderdale FL;2017."},{"key":"e_1_2_12_98_1","unstructured":"PolakS PatelN Rowland YeoK JameiM.Assessing formulation attributes' impact on local and systemic exposure of clindamycin after topical applciation of pro\u2010drug clindamycin phosphate using PBPK modelling. Controlled Release Society Annual Meeting; New York USA;2018."},{"key":"e_1_2_12_99_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12551482"},{"key":"e_1_2_12_100_1","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12551488"},{"key":"e_1_2_12_101_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01106105"},{"key":"e_1_2_12_102_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2011.175"},{"key":"e_1_2_12_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6336(11)80062-8"},{"key":"e_1_2_12_104_1","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.19593"},{"key":"e_1_2_12_105_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb02696.x"},{"key":"e_1_2_12_106_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2019.06.002"},{"key":"e_1_2_12_107_1","doi-asserted-by":"publisher","DOI":"10.1159\/000501732"},{"key":"e_1_2_12_108_1","doi-asserted-by":"publisher","DOI":"10.1016\/0031-6865(94)00047-Y"},{"key":"e_1_2_12_109_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.20549"},{"key":"e_1_2_12_110_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015956705293"},{"key":"e_1_2_12_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2012.04.011"},{"key":"e_1_2_12_112_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2007.06.001"},{"key":"e_1_2_12_113_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-3659(02)00321-8"},{"key":"e_1_2_12_114_1","unstructured":"PolakS MendykA PatelN.Combining machine learning and mechanistic modeling approaches to solve real life problems \u2010 assessment of the local tissue binding and its influence on the systemic exposure after topical application of drugs. American Conference on Pharmacometrics; Fort Lauderdale FL USA;2018."},{"key":"e_1_2_12_115_1","doi-asserted-by":"publisher","DOI":"10.1002\/jps.23245"}],"container-title":["CPT: Pharmacometrics &amp; Systems Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.12814","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/psp4.12814","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/psp4.12814","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,30]],"date-time":"2023-12-30T04:20:26Z","timestamp":1703910026000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/psp4.12814"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,27]]},"references-count":114,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["10.1002\/psp4.12814"],"URL":"https:\/\/doi.org\/10.1002\/psp4.12814","archive":["Portico"],"relation":{},"ISSN":["2163-8306","2163-8306"],"issn-type":[{"value":"2163-8306","type":"print"},{"value":"2163-8306","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,27]]},"assertion":[{"value":"2021-11-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}